Response of biochemical markers of bone turnover to hormone replacement therapy: Impact of biological variability

Journal of Bone and Mineral Research

Volumn 13, Issue 7, 1998, Pages 1124-1133

  Hannon, Rosemary ^a,b   Blumsohn, Aubrey ^a   Naylor, Kim ^a   Eastell, Richard ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b NORTHERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACID PHOSPHATASE; ALKALINE PHOSPHATASE; BIOCHEMICAL MARKER; CALCIUM; DEOXYPYRIDINOLINE; ESTRADIOL; HYDROXYPROLINE; OSTEOCALCIN;

ADULT; AGED; AMINO TERMINAL SEQUENCE; ARTICLE; BONE TURNOVER; CLINICAL ARTICLE; FEMALE; HORMONE SUBSTITUTION; HUMAN; OSTEOLYSIS; POSTMENOPAUSE;

ACID PHOSPHATASE; AGE FACTORS; ALKALINE PHOSPHATASE; AMINO ACIDS; BIOLOGICAL MARKERS; BONE DENSITY; BONE REMODELING; DENSITOMETRY, X-RAY; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; FEMALE; HUMANS; HYDROXYPROLINE; ISOENZYMES; LUMBAR VERTEBRAE; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PEPTIDE FRAGMENTS; PROCOLLAGEN;

EID: 0031836670     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/jbmr.1998.13.7.1124     Document Type: Article

References (36)

1. Stevenson JC, Cust MP, Gangar KF, Hillard TC, Lees B, Whitehead MI 1990 Effects of transdermal versus oral hormone replacement therapy on bone density in spine and proximal femur in postmenopausal women. Lancet 336:265-270.
2. Munk-Jensen N, Nielsen SP, Obel EB, Epikse PB 1988 Reversal of postmenopausal bone loss by oestrogen and progestogen: A double blind placebo controlled study. Br Med J 296:1150-1152.
3. Ribot C, Tremollieres F, Pouilles JM, Louvet JP, Peyron R 1990 Preventive effects of transdermal administration of 17β-estradiol on postmenopausal bone loss: A 2 year prospective study. Obstet Gynecol 75:425-465.
4. Castelo-Branco C, Pons F, Gonzalez-Merlo J 1993 Bone mineral density in surgically postmenopausal women receiving hormonal replacement therapy as assessed by dual photon absorptiometry. Maturitas 16:133-137.
5. Steiniche T, Hasling C, Charles P, Eriksen EF, Mosekilde L, Meisen F 1989 A randomised study on the effects of estrogen/ gestogen or high dose oral calcium on trabecular bone remodeling in postmenopausal osteoporosis. Bone 10:313-320.
6. Lufkin EG, Wahner HW, O'Fallon WM, Hodgson SF, Kotowicz MA, Lane AW, Judd HL, Caplan RH, Riggs BL 1992 Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann Intern Med 117:1-9.
7. Eriksen EF 1986 Normal and pathological remodeling of human trabecular bone: Three dimensional reconstruction of the remodeling sequence in normal and in metabolic bone disease. Endocr Rev 7:379-407.
8. Panteghini M, Pagani F 1996 Biological variation in urinary excretion of pyridinium crosslinks: Recommendations for the optimum specimen. Ann Clin Biochem 33:36-42.
9. Fraser CG, Harris EK 1989 Generation and application of data on biological variation in clinical chemistry. Crit Rev Clin Lab Sci 27:409-439.
10. Blumsohn A 1996 Biochemical assessment of bone turnover in man:sources of variability. Ph.D. thesis.
11. Hillard TC, Whitcroft SJ, Marsh MS, Ellerington MC, Lees B, Whitehead MI, Stevenson JC 1994 Long-term effects of transdermal and oral hormone replacement therapy on postmenopausal bone loss. Osteoporos Int 4:341-348.
12. Rosen CJ, Chesnut III CH, Mallinak NJS 1997 The predictive value of biochemical markers of bone turnover for bone mineral density in early postmenopausal women treated with hormone replacement or calcium supplementation. J Clin Endocrinol Metab 82:1904-1910.
13. Torgerson DJ, Donaldson C, Russell IT, Reid DM 1995 Hormone replacement therapy: Compliance and cost after screening for osteoporosis. Eur J Obstet Gynecol Reprod Biol 59:57-60.
14. Davis JW, Ross PD, Wasnich RD, MacLean CJ, Vogel JM 1991 Long-term precision of bone loss rate measurements among postmenopausal women. Calcif Tissue Int 48:311-318.
15. Adami S, Suppi R, Bertoldi F, Rossini M, Residori M, Maresca V, Loaseio V 1989 Transdermal estradiol in the treatment of postmenopausal bone loss. Bone Miner 7:79-86.
16. Uebelhart D, Schlemmer A, Johansen JS, Gineyts E, Christiansen C, Delmas PD 1991 Effect of menopause and hormone replacement therapy on the urinary excretion of pyridinium crosslinks. J Clin Endocrinol Metab 72:367-373.
17. Hasling C, Eriksen EF, Melkko J, Risteli L, Charles P, Mosekilde L, Risteli J 1991 Effects of a combined estrogengestagen regimen on serum levels of the carboxy-terminal Propeptide of human type-I procollagen in osteoporosis. J Bone Miner Res 6:1295-1300.
18. Colwell A, Russell RGG, Eastell R 1993 Factors affecting the assay of urinary 3-hydroxy pyridinium crosslinks of collagen as markers of bone resorption. Eur J Clin Invest 23:341-349.
19. Efron B 1979 Bootstrap methods: Another look at the jacknife. Ann Statist 7:1-26.
20. Panteghini M, Pagani F 1995 Biological variation in bone-derived biochemical markers in serum. Scand J Clin Lab Invest 55:609-616.
21. Stevenson HP, Leslie H, Sheridan B 1997 Intra-individual variation in serum type I procollagen caboxy-terminal propeptide and type I collagen carboxy-terminal cross-linked telopeptide concentrations. Ann Clin Biochem 34:317-318.
22. Gertz BJ, Shao P, Hanson DA, Quan H, Harris ST, Genant HK, Chesnut CH III, Eyre DR 1994 Monitoring bone resorption in early postmenopausal women by an immunoassay for cross-linked collagen peptides in urine. J Bone Miner Res 9:135-142.
23. Colwell A, Eastell R 1996 The renal clearance of free and conjugated pyridinium crosslinks of collagen. J Bone Miner Res 11:1976-1980.
24. Gasser A, Celada A, Courvoisier B, Depierre D, Hulme PM, Rinsler M, Williams D, Wootton R 1979 The clinical measurement of urinary total hydroxyproline excretion. Clin Chim Acta 95:487-491.
25. Vasikaran SD, McCloskey EV, Kahn S, Kanis JA 1994 Intraindividual variation in fasting urinary calcium-and hydroxyproline-creatinine ratios measured in metabolic bone clinic patients as both outpatients and inpatients. Ann Clin Biochem 31:272-276.
26. Garnero P, Shih WJ, Gineyts E, Kalpf D, Delmas PD 1994 Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab 79:1693-1700.
27. Ho KKY, Weissberger AJ 1992 Impact of short-term estrogen administration on growth hormone secretion and action-Distinct route-dependent effects on connective and bone tissue metabolism. J Bone Miner Res 7:821-827.
28. Bellantoni MF, Vittone J, Campfield AT, Bass KM, Harman SM, Blackman MR 1996 Effects of oral versus transdermal estrogen on the growth hormone/insulin-like growth factor I axis in younger and older postmenopausal women: A clinical research center study. J Clin Endocrinol Metab 81:2848-2853.
29. Friend KE, Hartman ML, Pezzoli SS, Clasey JL, Thorner MO 1996 Both oral and transdermal estrogen increase growth hormone release in postmenopausal women-A clinical research center study. J Clin Endocrinol Metab 81:2250-2256.
30. Hassager C, Fabbri-Marbelli G, Christiansen C 1993 The effect of the menopause and hormone replacement therapy on serum carboxy-terminal propeptide of type I collagen. Osteoporos Int 3:50-52.
31. Prestwood KM, Pilbeam CC, Burleson JA, Woodiel FN, Delmas P, Deftos LJ, Raisz LG 1994 The short term effects of conjugated estrogen on bone turnover in older women. J Clin Endocrinol Metab 79:366-371.
32. Hassager C, Jensen LT, Johansen JS, Riis BJ, Melkko J, Podenphant J, Risteli L, Christiansen C, Risteli J 1991 The carboxy-terminal propeptide of type I procollagen in serum as a marker of bone formation: The effect of nandrolone decanoate and female sex hormones. Metabolism 40:205-208.
33. Garnero P, Gineyts E, Arbault P, Christiansen C, Delmas PD 1995 Different effects of bisphosphonate and estrogen therapy on the excretion of free and peptide-bound crosslinks. J Bone Miner Res 10:641-649.
34. Blumsohn A, Naylor KE, Assiri AM, Eastell R 1995 Different responses of biochemical markers of bone resorption to bisphosphonate therapy in Paget disease. Clin Chem 41:1592-1598.
35. Riis BJ, Overgaard K, Christiansen C 1995 Biochemical markers of bone turnover to monitor the bone response to post-menopausal hormone replacement therapy. Osteoporos Int 5:276-280.
36. Hassager C, Jensen SB, Christiansen C 1994 Non-responders to hormone replacement therapy for the prevention of post-menopausal bone loss: Do they exist? Osteoporos Int 4:36-41.